Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $110 to $135.
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $110 to $135.